In a move that is not unfamiliar to those in the industry, the U.S. Food & Drug Administration (FDA) has recently made a proposal to regulate laboratory-developed tests (LDTs) as medical devices. Announced on October 3, this anticipated decision is part of a Proposed Rule.
Laboratory-developed tests (LDTs) are tests created and offered by individual clinical laboratories and presently form the vast majority of today’s clinical laboratory testing. Ironically, their regulatory status has been a topic of interest and debate for many years within the medical and legal community.
The decision by the FDA to propose the regulation of these LDTs as medical devices is a move that will have significant implications for not only the labs that develop these tests but for the broader healthcare sector as a whole.
The anticipation surrounding the Proposed Rule has indeed been high. Until full text of the proposal is available, it will be hard to gauge the complete extent of the impact it will have. However, the decision certainly has potential to effect a sea change, and it is therefore prudent for those involved in clinical laboratory testing to keep a close eye on the developments.
For more in-depth details on this announcement, you can access the publication here. It is recommended that stakeholders continue to monitor this issue closely.
This article will be updated as more information becomes available. Until then, legal professionals and healthcare providers need to keep their ear to the ground to stay informed about the ongoing discussions around this matter.